John Trent Warren

US Patent:

6376197, Apr 23, 2002

Filed:

May 22, 2000

Appl. No.:

09/576396

Inventors:

Susan K. Keay - Ellicott City MD
John W. Warren - Baltimore MD
Michael K. Hise - Columbia MD

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

G01N 3353

US Classification:

435 71, 435 12, 436501, 530350, 530399

Abstract:

Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause epithelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin bindingâepidermal growth factor-like growth factor (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.

US Patent:

20010000783, May 3, 2001

Filed:

Dec 20, 2000

Appl. No.:

09/742140

Inventors:

Susan Keay - Ellicott City MD, US
John Warren - Baltimore MD, US
Michael Hise - Columbia MD, US

International Classification:

A61K031/70
A01N043/04

US Classification:

514/002000, 514/044000, 435/007100

Abstract:

Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that human bladder epithelial cells from both normal controls and IC patients are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause epithelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that 1) levels of heparin binding—epidermal growth factor-like growth factor (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis; 2) the APF found in IC urine specimens inhibits HB-EGF production by bladder epithelial cells; and 3) that the administration of rHB-EGF blocks the effects of APF on bladder epithelial cells from either IC patients or controls. The invention herein is directed to the administration of HB-EGF, or a functional derivative or agonist thereof, to bladder epithelial cells to inhibit the effects of APF on bladder cell proliferation, thereby reducing or eliminating the chronic damage to the bladder epithelium. HB-EGF or a functional derivative may be used as a therapy for patients suffering from IC or other diseases characterized by inhibited epithelial cell proliferation.

US Patent:

20020016443, Feb 7, 2002

Filed:

Apr 21, 2001

Appl. No.:

09/839859

Inventors:

Susan Keay - Ellicott City MD, US
John Warren - Baltimore MD, US
Michael Kleinberg - Baltimore MD, US
Michael Hise - Columbia MD, US

International Classification:

G01N033/53
G01N033/567
A61K039/395
C12N015/12
C12P021/00

US Classification:

530/350000, 424/130100, 435/007200, 514/002000, 536/023500

Abstract:

The invention relates to a novel antiproliferative factor (APF) present in urine of patients with interstitial cystitis (IC). APF is useful as a marker for disease activity and its antagonists are useful as therapeutic medicaments for IC and other conditions associated with elevated APF. APF and its agonists are useful in the treatment of diseases associated with cell proliferation, such as bladder cancer.

US Patent:

20090307339, Dec 10, 2009

Filed:

Jun 9, 2008

Appl. No.:

12/135946

Inventors:

Marie Louise Setnes - Minneapolis MN, US
John Sebastian Warren - Durham NC, US

International Classification:

G06F 15/177

US Classification:

709222

Abstract:

A method in one embodiment includes establishing communication between a master node and several federated nodes, wherein each node is an instance of a distributed application; initializing the distributed application, wherein the initialization includes the federated nodes processing data local thereto and providing information about the local data to the master node; and after initialization, at run time, receiving data requests, wherein the master node services the data requests by routing the requests to the nodes. A method in another embodiment includes establishing communication between a master node and several federated nodes, wherein each node is an instance of a distributed application; initializing the distributed application, including gathering information about local data associated with each of the federated nodes, the information including associations of local data across multiple federated nodes; and after initialization, at run time, receiving data requests, wherein the master node services the data requests by routing the requests to one of the nodes believed to have the requested data.

US Patent:

47096381, Dec 1, 1987

Filed:

Sep 24, 1981

Appl. No.:

6/305077

Inventors:

David E. Broden - Minnetonka MN
Wilford E. Martwick - New Hope MN
John B. Warren - Wayzata MN

Assignee:

Honeywell Inc. - Minneapolis MN

International Classification:

F42B 1316

US Classification:

102522

Abstract:

A low dispersion discarding sabot projectile comprising: a full caliber cylindrically shaped pusher having a cup-like forward facing recess concentric with the external surface of said pusher, a circumferential groove for receiving a rotation ring, said groove being positioned in approximate radial register with a rear surface of said recess, and a concave recess in the rear end face of said pusher; a cylindrically shaped subcaliber projectile having: (i) a rear portion adapted to be inserted into said forward facing recess of said pusher, (ii) a main body portion projecting forward from said pusher, and (iii) a nose portion; and a discarding sabot of lightweight frangible material disposed around said main body portion, the forward portion of said sabot being spaced radially away from the external surface of said nose portion.

US Patent:

61565229, Dec 5, 2000

Filed:

Jul 2, 1998

Appl. No.:

9/109548

Inventors:

Susan K. Keay - Ellicott City MD
John W. Warren - Baltimore MD
Michael K. Hise - Columbia MD

Assignee:

University of Maryland Baltimore - Baltimore MD

International Classification:

G01N 3353

US Classification:

435 71

Abstract:

Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative fact (APF) present in IC urine specimens. Inhibited proliferation may cause epthelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding--epidermal growth factor-like growth fact (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.

US Patent:

59626453, Oct 5, 1999

Filed:

Oct 3, 1997

Appl. No.:

8/944202

Inventors:

Susan Keay - Ellicott City MD
John W. Warren - Baltimore MD
Michael Kleinberg - Baltimore MD
Michael K. Hise - Ellicott City MD

Assignee:

University of Maryland - Baltimore MD

International Classification:

C07K 100
C12G 100
G01N 33574

US Classification:

530350

Abstract:

A novel antiproliferative factor (APF) present in urine of patients with interstitial cystitis (IC) is described. This urine antiproliferative factor can serve as a marker for disease activity and its antagonists as therapeutic medicaments for IC. In addition, APF and its agonists can be used for treating diseases associated with cell proliferation.

US Patent:

62322893, May 15, 2001

Filed:

Apr 16, 1999

Appl. No.:

9/293037

Inventors:

Susan Keay - Ellicott City MD
John Warren - Baltimore MD
Michael Hise - Columbia MD

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

C07K 1400

US Classification:

514 2

Abstract:

Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that human bladder epithelial cells from both normal controls and IC patients are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause epithelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that 1) levels of heparin binding-epidermal growth factor-like growth factor (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis; 2) the APF found in IC urine specimens inhibits HB-EGF production by bladder epithelial cells; and 3) that the administration of rHB-EGF blocks the effects of APF on bladder epithelial cells from either IC patients or controls. The invention herein is directed to the administration of HB-EGF, or a functional derivative or agonist thereof, to bladder epithelial cells to inhibit the effects of APF on bladder cell proliferation, thereby reducing or eliminating the chronic damage to the bladder epithelium. HB-EGF or a functional derivative may be used as a therapy for patients suffering from IC or other diseases characterized by inhibited epithelial cell proliferation.